Time filter

Source Type

GETTYSBURG, PA--(Marketwired - May 15, 2017) - OPEN MINDS has announced that Andrew Wright, Vice President of Digital Medicine at Otsuka America Pharmaceutical, Inc. and James Schuster, MD, Vice President of Behavioral Integration & Chief Medical Officer of Behavioral Health and Medicaid Services at UPMC Insurance Division will keynote the 2017 OPEN MINDS Technology & Informatics Institute. This year's institute will be held on November 7-8, 2017 at the Loews Philadelphia Hotel, in Philadelphia, Pennsylvania. This executive-focused event projects over 500 attendees and more than 30 innovative technology organizations and will focus on mastering the tech tools and strategies you need to maximize performance in a competitive market. This year's institute is focused on the technology tools and strategies organizations need to maximize performance in a competitive, value-based market. This year, we're exploring all the tech tools and competencies successful executives must master to build successful and sustainable organizations. This event aims to bring together executives from across the health and human services industry to discuss the emerging technology tools executives need to improve outcomes, streamline decisionmaking, and add value to the management and delivery of care for consumers with complex needs. Andrew Wright will kick-off the OPEN MINDS Technology & Informatics Institute on November 7 with his plenary address, "Pharmaceuticals & Digital Medicine -- Developments In Collaborative Innovation." Mr. Wright is Vice President of Digital Medicine at Otsuka America Pharmaceutical, Inc. (OAPI). In this role, he is responsible for leading the commercialization of wearable computing and digital products. OAPI's goal is to enable improved patient medication adherence and better-informed physician decisionmaking to tailor treatment to the patient's needs. Mr. Wright has more than 25 years of U.S. and Global experience in commercial leadership roles in the pharmaceutical industry. Previously, he worked at Novartis as Head, HCP Digital/Multi-Channel Marketing, Global Commercialization, and was responsible for identifying and developing digital and multi-channel solutions that enhanced customer engagement. Prior to that, as Executive Director of Insights & Innovation, he led and developed a team responsible for customer/brand insights and innovation across the U.S. pharmaceutical business. Day two of this year's event will begin with a plenary address, "The Future Role Of Medicare & Medicaid Health Plans: Data Sharing To Enable Population Health Management," by Dr. James Schuster. Dr. Schuster is Vice President of Behavioral Integration and Chief Medical Officer of Behavioral Health and Medicaid Services at UPMC Insurance Division and has been with the insurance division since 2000. At the insurance division, Dr. Schuster is responsible for medical leadership of behavioral health, physical health, and long term supportive services products. Dr. Schuster has been a leader in development of recovery and pharmacy quality improvement programs and has received awards from the Patient Centered Outcomes Research Institute to assess the impact of, physical health/behavioral health integration programs and shared decision making initiatives. He is an Adjunct Professor in the Department of Psychiatry at the University of Pittsburgh. "Improving value, with both better performance and lower costs, is imperative to succeeding in today's health and human services market. And improving value when working with consumers with complex needs can be impossible without adopting new and innovative technologies," explains Monica E. Oss, OPEN MINDS Chief Executive Officer. "Organizations need to being using data, communication technologies, robotics, and consumer-directed treatment technologies to meet and exceed the requirements in today's market. It is critical that leadership teams recognize and understand the value of today's tech tools and can master the tech strategies needed to maximize their organization's performance in this competitive marketplace." Group discounts are available for The 2017 OPEN MINDS Technology & Informatics Institute. Early registration is highly encouraged as this event is expected to sell out quickly. Register today or learn more at https://technology.openminds.com/. OPEN MINDS is a national strategic advisory firm specializing in the sectors of the health and human service industry serving individuals with complex support needs: mental health; addiction treatment; children and family services; intellectual and developmental disabilities; chronic disease management; long term care; social services; correctional health care; and juvenile justice. Founded in 1987 and based in Gettysburg, Pennsylvania, the 75+ associates believe by providing the latest market intelligence and management best practices to organizations serving the health and social support needs of the most vulnerable consumers, those organizations will be better able to provide efficient and effective services. Learn more at www.openminds.com. For additional questions and inquiries, please contact Sarah C. Threnhauser, Executive Vice President, OPEN MINDS at 717-334-1329 or openminds@openminds.com.


News Article | May 3, 2017
Site: www.biosciencetechnology.com

A new study has found brain abnormalities in people with bipolar disorder. In the largest MRI study to date on patients with bipolar disorder, a global consortium published new research showing that people with the condition have differences in the brain regions that control inhibition and emotion. By revealing clear and consistent alterations in key brain regions, the findings published in Molecular Psychiatry on May 2 offer insight to the underlying mechanisms of bipolar disorder. "We created the first global map of bipolar disorder and how it affects the brain, resolving years of uncertainty on how people's brains differ when they have this severe illness," said Ole A. Andreassen, senior author of the study and a professor at the Norwegian Centre for Mental Disorders Research at the University of Oslo. Bipolar disorder affects about 60 million people worldwide, according to the World Health Organization. It is a debilitating psychiatric disorder with serious implications for those affected and their families. However, scientists have struggled to pinpoint neurobiological mechanisms of the disorder, partly due to the lack of sufficient brain scans. The study was part of an international consortium led by the USC Stevens Neuroimaging and Informatics Institute at the Keck School of Medicine of USC: ENIGMA (Enhancing Neuro Imaging Genetics Through Meta Analysis) spans 76 centers and includes 26 different research groups around the world. The researchers measured the MRI scans of 6,503 individuals, including 2,447 adults with bipolar disorder and 4,056 healthy controls. They also examined the effects of commonly used prescription medications, age of illness onset, history of psychosis, mood state, age and sex differences on cortical regions. The study showed thinning of gray matter in the brains of patients with bipolar disorder when compared with healthy controls. The greatest deficits were found in parts of the brain that control inhibition and motivation -- the frontal and temporal regions. Some of the bipolar disorder patients with a history of psychosis showed greater deficits in the brain's gray matter. The findings also showed different brain signatures in patients who took lithium, anti-psychotics and anti-epileptic treatments. Lithium treatment was associated with less thinning of gray matter, which suggests a protective effect of this medication on the brain. "These are important clues as to where to look in the brain for therapeutic effects of these drugs," said Derrek Hibar, first author of the paper and a professor at the USC Stevens Neuroimaging and Informatics Institute when the study was conducted. He was a former visiting researcher at the University of Oslo and is now a senior scientist at Janssen Research and Development, LLC. Future research will test how well different medications and treatments can shift or modify these brain measures as well as improve symptoms and clinical outcomes for patients. Mapping the affected brain regions is also important for early detection and prevention, said Paul Thompson, director of the ENIGMA consortium and co-author of the study. "This new map of the bipolar brain gives us a roadmap of where to look for treatment effects," said Thompson, an associate director of the USC Stevens Neuroimaging and Informatics Institute at the Keck School of Medicine. "By bringing together psychiatrists worldwide, we now have a new source of power to discover treatments that improve patients' lives."


News Article | May 2, 2017
Site: www.eurekalert.org

A new study has found brain abnormalities in people with bipolar disorder. In the largest MRI study to date on patients with bipolar disorder, a global consortium published new research showing that people with the condition have differences in the brain regions that control inhibition and emotion. By revealing clear and consistent alterations in key brain regions, the findings published in Molecular Psychiatry on May 2 offer insight to the underlying mechanisms of bipolar disorder. "We created the first global map of bipolar disorder and how it affects the brain, resolving years of uncertainty on how people's brains differ when they have this severe illness," said Ole A. Andreassen, senior author of the study and a professor at the Norwegian Centre for Mental Disorders Research at the University of Oslo. Bipolar disorder affects about 60 million people worldwide, according to the World Health Organization. It is a debilitating psychiatric disorder with serious implications for those affected and their families. However, scientists have struggled to pinpoint neurobiological mechanisms of the disorder, partly due to the lack of sufficient brain scans. The study was part of an international consortium led by the USC Stevens Neuroimaging and Informatics Institute at the Keck School of Medicine of USC: ENIGMA (Enhancing Neuro Imaging Genetics Through Meta Analysis) spans 76 centers and includes 26 different research groups around the world. The researchers measured the MRI scans of 6,503 individuals, including 2,447 adults with bipolar disorder and 4,056 healthy controls. They also examined the effects of commonly used prescription medications, age of illness onset, history of psychosis, mood state, age and sex differences on cortical regions. The study showed thinning of gray matter in the brains of patients with bipolar disorder when compared with healthy controls. The greatest deficits were found in parts of the brain that control inhibition and motivation -- the frontal and temporal regions. Some of the bipolar disorder patients with a history of psychosis showed greater deficits in the brain's gray matter. The findings also showed different brain signatures in patients who took lithium, anti-psychotics and anti-epileptic treatments. Lithium treatment was associated with less thinning of gray matter, which suggests a protective effect of this medication on the brain. "These are important clues as to where to look in the brain for therapeutic effects of these drugs," said Derrek Hibar, first author of the paper and a professor at the USC Stevens Neuroimaging and Informatics Institute when the study was conducted. He was a former visiting researcher at the University of Oslo and is now a senior scientist at Janssen Research and Development, LLC. Future research will test how well different medications and treatments can shift or modify these brain measures as well as improve symptoms and clinical outcomes for patients. Mapping the affected brain regions is also important for early detection and prevention, said Paul Thompson, director of the ENIGMA consortium and co-author of the study. "This new map of the bipolar brain gives us a roadmap of where to look for treatment effects," said Thompson, an associate director of the USC Stevens Neuroimaging and Informatics Institute at the Keck School of Medicine. "By bringing together psychiatrists worldwide, we now have a new source of power to discover treatments that improve patients' lives." Founded in 1885, the Keck School of Medicine of USC is among the nation's leaders in innovative patient care, scientific discovery, education, and community service. It is part of Keck Medicine of USC, the University of Southern California's medical enterprise, one of only two university-owned academic medical centers in the Los Angeles area. This includes the Keck Medical Center of USC, composed of the Keck Hospital of USC and the USC Norris Cancer Hospital. The two world-class, USC-owned hospitals are staffed by more than 500 physicians who are faculty at the Keck School. The school today has approximately 1,650 full-time faculty members and voluntary faculty of more than 2,400 physicians. These faculty direct the education of approximately 700 medical students and 1,000 students pursuing graduate and post-graduate degrees. The school trains more than 900 resident physicians in more than 50 specialty or subspecialty programs and is the largest educator of physicians practicing in Southern California. Together, the school's faculty and residents serve more than 1.5 million patients each year at Keck Hospital of USC and USC Norris Cancer Hospital, as well as USC-affiliated hospitals Children's Hospital Los Angeles and Los Angeles County + USC Medical Center. Keck School faculty also conduct research and teach at several research centers and institutes, including the USC Norris Comprehensive Cancer Center, the Zilkha Neurogenetic Institute, the Eli and Edythe Broad Center for Stem Cell Research and Regenerative Medicine at USC, the USC Cardiovascular Thoracic Institute, the USC Roski Eye Institute and the USC Institute of Urology. In 2016, U.S. News & World Report ranked Keck School of Medicine among the Top 40 medical schools in the country. For more information, go to keck.usc.edu.


GETTYSBURG, PA--(Marketwired - October 31, 2016) - New this year, OPEN MINDS will have an exciting demo track at The 2016 OPEN MINDS Technology & Informatics Institute. This two-day executive education event will be held on November 10-11, 2016 at the Marriott Wardman Park Hotel in Washington, D.C. and will feature four in-depth demonstrations of state-of-the-art technologies from organizations such as: Askesis Development Group, an innovative electronic health record (EHR) vendor, will unveil its next generation software solution, PsychConsult Encounter Navigator, developed to provide a patient-centered method for documenting psychiatric and primary care services for physical health, substance use, and behavioral health providers. This tool supports an integrated care team approach and is driven by a physician driven workflow. PsychConsult Encounter Navigator organizes the complex components of evaluation and management documentation and dynamically prompts clinicians for suggested interventions to improve clinical decision making. This session will showcase how PsychConsult Encounter Navigator can support an integrated care team approach and improve quality of care. IBM Watson Health, a unit within IBM -- a leading innovative technology vendor, will highlight ways technology can be used in health care. The IBM Watson Health and ODH, Inc. team will showcase the importance of population health management and ways cognitive computing is now being used in health care including behavioral health and the health and human services marketplaces. The Echo Group, a leading behavioral health EHR vendor, will showcase its unique ability to partner with organizations aiming to succeed with becoming a Certified Community Behavioral Health Clinic (CCBHC). As CCBHCs and the Excellence in Mental Health Act have revolutionize behavioral health care, The Echo Group is partnering with customers in 17 states that were awarded planning grants to provide the product and leadership necessary to be selected CCBHCs in those states. The Echo Group will highlight its expertise with staying on top of the evolving CCBHC initiative and adapting the new standards and requirements to organizations. PLEXIS Healthcare Systems, a leading payer technology vendor, will highlight its enterprise core administration and claims management solution for healthcare payers, government healthcare, health plans, and payer provider collaborations. The PLEXIS team aims to showcase how its first-in-class solutions can be used to implement a new service line into the system, for purposes such as billing, in as little as 30-minutes. This demo will also highlight how the PLEXIS system can assist with encounter data reporting and full service EDI as well as easily integrate with an EHR system to support and improve core administration and claims management functions. Along with these demonstrations, the agenda will feature two exciting keynote presenters: This year's institute will have a special focus on tech-enabled clinical performance improvement -- and the state-of-the-art technologies that can make that happen. Many provider organizations are using data to improve their revenue cycle management, to manage productivity, and create other administrative efficiencies; but, the path to deploying data and emerging technologies to improve the access to, and outcomes of, clinical services is more difficult. The 2016 OPEN MINDS Technology & Informatics Institute is about making technology work for your organization in the new era of value-based care. This year's institute will have four tracks that will provide all the cutting-edge information your team needs to improve outcomes and decisionmaking through technology: Track 1, Technology Strategy, is about building foundations for the organization's technology plan. All technology investments should be a derivative outgrowth of your organization's strategic plan and be grounded in the fundamental needs of the organization, their consumers, and their payers. This track focuses on best practice technology planning, budgeting, selection, and implementation -- the essential components needed to compete in a value-based market. Track 2, Technology Innovation, is focused on highlighting the range of emerging technology options available. From robots to smartphone apps, the technology is shaping the delivery of health care from every angle -- but not all tech is a good fit for every organization, or every consumer. This track is designed to showcase the many cutting-edge technologies that are shaping the future of health care and to explore how organizations are using this new tech to gain the competitive advantage in their markets. Track 3, Knowledge Partners, is designed to showcase the experiences of provider organizations from across the country. In partnership with some of the industry's most advanced technology vendors, this track will highlight how vendor and provider organization partnerships can help to position organizations for success in a value-based market through the use of information management and new technologies. Track 4, Technology Demonstrations, is about evaluating the range of vendor offerings available to provider organizations. In this market, suppliers of technology are no longer just "vendors," but partners for the long term. This exciting track will allow executives to learn more about their options, ask questions, and find the technology partner that's a best fit. Seating for The 2016 OPEN MINDS Technology & Informatics Institute is limited, and registrations will be sold on a first-come, first-serve basis. To register online or download a registration form, visit https://technology.openminds.com/register. OPEN MINDS is a national strategic advisory firm specializing in the sectors of the health and human service industry serving individuals with complex support needs: mental health; addiction treatment; children and family services; intellectual and developmental disabilities; chronic disease management; long term care; social services; correctional health care; and juvenile justice. Founded in 1987 and based in Gettysburg, Pennsylvania, the 75+ associates believe by providing the latest market intelligence and management best practices to organizations serving the health and social support needs of the most vulnerable consumers, those organizations will be better able to provide efficient and effective services. Learn more at www.openminds.com. For additional questions and inquiries, please contact Tim Snyder, Executive Vice President, OPEN MINDS at 717-334-1329 or openminds@openminds.com.


News Article | December 5, 2016
Site: www.businesswire.com

ISTANBUL--(BUSINESS WIRE)--Turkcell (NYSE:TKC) (BIST:TCELL) has signed a memorandum of understanding (MoU) with Istanbul Technical University (ITU) to strategically cooperate on the development of 5G technologies. Within the frame of the contract signed, Turkcell and ITU will carry out mutual studies in Research & Development and education areas to make Turkey a producing country in 5G technology. Turkcell has signed an agreement to carry out work in partnership with Istanbul Technical University for developing 5G technologies in Turkey. Within the frame of the protocol signed by Istanbul Technical University Rector Prof. Dr. Mehmet Karaca, Turkcell CEO Kaan Terzioğlu and Istanbul Technical University Informatics Institute Director Prof. Dr. Ertugrul Karacuha, Turkcell and Istanbul Technical University are going to carry out mutual R&D studies on 5G. The ultimate aim of ITU and Turkcell in signing this contract is to make Turkey a producing country in 5G technology. "In line with Turkey’s targets for 2023, we will continue our mission of collaboration with industry. R&D activities to be carried out in both application and mobile communication systems will provide significant contribution to the future competitiveness of our country. I would like to emphasize that the project carried out with Turkcell is a start point in this regard." said Prof. Dr. Mehmet Karaca, Istanbul Technical University Rector. "Currently Turkey has one of the most prepared infrastructures in the world for 5G. We, as Turkcell, believe that 5G technologies can be a milestone for our country to become a producing country. And our top-priority target is to see Turkey as the leader of the countries that have developed 5G and to allow it to be an arbiter in this area with our collaboration with ITU. For this purpose, we are going to work together with the best engineers both at our company and at ITU to establish a 5G centre in the campus of the university," said Kaan Terzioğlu, Turkcell CEO. "With ITU and Turkcell collaboration, in regard with 5G we are going to found an open-area test, measurement and research centre and make it available for everyone who carry out R&D activities. We also aim to develop products locally in Turkey and contribute to local production within the frame of new technologies. This will ensure participation in standardization studies in the world for 5G," said Istanbul Technical University Informatics Institute Director Prof. Dr. Ertugrul Karacuha. Within the frame of this collaboration, the plan is to conduct studies for increasing the competitiveness of Turkey in regard with 5G by using The Department of Electronics and Communications Engineering, Computer Engineering Institute of Informatics, High Performance Computing Centre, laboratories and technical infrastructure opportunities at ITU. This collaboration will also provide an excellent opportunity for ITU students to take part in 5G studies and make contributions. ITU and Turkcell are going to act together at scientific events such as conferences, symposiums, seminars, workshops and panel discussions regarding national and international 5G projects, as well as R&D studies. Within the scope of the agreement that ensures cooperation also in the standardisation studies regarding the next generation telecommunications, Turkcell and ITU are going to create an infrastructure at the university for "ITU-Cell Research, Development and Test Environment" to make the Ayazağa Campus of ITU a 5G centre.


Matisziw T.C.,Informatics Institute | Lee C.-L.,University of Missouri | Grubesic T.H.,Drexel University
Journal of Air Transport Management | Year: 2012

The US federal Essential Air Service program was established to subsidize air service to communities unable to retain commercial carriers after airline deregulation in 1978. In this paper, the subsidized service between program communities and commercial hub airports is investigated relative to several Essential Air Service planning objectives. Specifically, observed community hubbing activity is compared with that modeled to minimize hub access cost and maximize community accessibility within the commercial air transport system. Results highlight trends in system performance relative to these planning objectives and indicate that significant potential exists for enhancing the efficiency of the program in light of limited resources. © 2011 Elsevier Ltd.


News Article | November 8, 2016
Site: www.prnewswire.com

ASHLAND, Ore., Nov. 8, 2016 /PRNewswire/ -- PLEXIS Healthcare Systems will demonstrate its flagship payer platform at the 2016 OPEN MINDS Technology and Informatics Institute in Washington D.C. on Nov. 10-11, 2016. PLEXIS will highlight its enterprise core administration and claims...


News Article | October 6, 2016
Site: www.biosciencetechnology.com

Brain size may matter. In the world's largest MRI study on brain size to date, USC researchers and their international colleagues identified seven genetic hotspots that regulate brain growth, memory and reasoning as well as influence the onset of Parkinson's disease. Most brain imaging studies evaluate around 100 people, but the Nature Neuroscience study published on Oct. 3 examined 32,438 adults, said Paul Thompson, a corresponding author and associate director of the USC Mark and Mary Stevens Neuroimaging and Informatics Institute. The results bring scientists closer to understanding the genetic program that builds the living brain. "Brain measures from MRI account for about 15 percent of the differences in our cognitive ability -- that is, brain-based skills required to perform simple and complex tasks," said Thompson, who led a team of more than 300 international scientists. "The genes underlying brain development have far-reaching effects that extend well beyond the initial years of life. You have genes that are beneficial for you and help build brain structures early in life. Yet some of these are harmful later in life and promote diseases such as Parkinson's." Parkinson's disease is a progressive disorder of the nervous system that affects movement and often leads to tremors. Like many other degenerative brain disorders, a cure does not yet exist. Although scientists have not determined an ideal healthy brain size, a brain that is too small (microcephaly) or too big (macrocephaly) can lead to abnormal cognitive development and lifelong challenges. The human brain reaches maximum size around a person's early 20s, Thompson said. The study used data on subjects from 52 study sites that are part of the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium and Enhancing Neuro Imaging Genetics through Meta Analysis (ENIGMA) consortium, which is based at USC and led by Thompson. The research supports the notion that brain size could be used as a measure of "brain reserve," meaning brain size can promote resilience to age-related brain diseases. ENIGMA is part of the USC Mark and Mary Stevens Neuroimaging and Informatics Institute, which aims to enhance discovery through the application of imaging and information techniques in the study of the brain. The institute is a leader in data acquisition, analysis stewardship and computational innovation for the purpose of biomedical research. Genes and environment come into play Both genetics and environmental factors affect brain size. Good diet, education and exercise build a healthy brain in young people and protect older people from tissue loss. "This research is on the leading edge of cracking the brain's genetic code," Thompson said. "Millions of people carry variations in their DNA that help boost or lower their brains' susceptibility to a vast range of diseases. Once we identify these genes, we can target them with drugs to reduce the risk of disease. People also can take preventive steps through exercise, diet and mental stimulation to erase the effects of a bad gene." The study began seven years ago. Its technique of using brain scans to identify gene hotspots provides more information than the traditional method of collecting DNA samples from patients. "Now that we can see a gene's imprint in brain scans, it's like capturing a thief red-handed," Thompson said. "You can chase it down brain pathways and circuits and discover what brain cells the gene is damaging. Using brain scans builds a foundation so that scientists in the future can better focus their studies on hotspots of interest." The seven genes and what they do Thompson and his colleagues identified five new gene hubs that predict brain growth and confirmed two known hotspots. The genes in these areas provide links between an individual's maximum brain size and processes such as: Researchers adjusted their data for height and confirmed growth predictions by examining 2,824 children from before birth until age 6. Of note, one of the areas of the human genome that affects brain size has a normal version and an inverted alphabet variant that evolved some 3 million years ago, Thompson said. "MAPT is one of the most dangerous genes in this inverted zone," he said. "It is implicated in neurodegenerative diseases such as frontotemporal dementia and Parkinson's, Alzheimer's and Lou Gehrig's disease. Even in the normal brain-size range, brain scans reveal telltale signs of future disease." Ongoing studies may reveal additional brain conditions that are promoted by the tau-associated MAPT gene, Thompson said. "The genetic program that builds our brains consists of growth factors, cancer genes, genes that promote dementia and genes that are crucial in helping the brain to form connections," Thompson said. "A complex interplay of factors makes some genes that are beneficial in early life go rogue later in life. It's extremely important to understand when genes that affect brain size -- such as the MAPT gene -- are helpful and what parts of the brain they are influencing."


Focus on applying latest technology to search, share and reuse data Network organization Amsterdam Data Science (ADS) signed an agreement with scientific information solutions provider Elsevier aimed at advancing data science research and education in Amsterdam. Both parties are embarking on a number of joint projects that will enable data scientists to access and share data and use the latest technology to collaborate and advance the field of data science together. Kajsa Ollongren, Alderperson and deputy mayor of the City of Amsterdam, supports the initiative: "The partnership between Elsevier and Amsterdam Data Science is great news for Amsterdam as it helps us to further develop the city as a hub in data science and attracting international technology talent.  Seeing our best educational and research institutes teaming up with Netherlands-based multinational science & health data company Elsevier will boost Amsterdam's international competitive position and improve the overall data tech climate in the greater Amsterdam metro area." ADS and Elsevier will collaborate together on several fronts, including research and development, joint promotion of Amsterdam as a data science center, and data science talent development. This partnership marks the first long-term collaboration agreement signed by ADS, an initiative of the University of Amsterdam, VU University, Amsterdam University of Applied Sciences and Centrum Wiskunde & Informatica. "Business and society are generating and storing more data than ever before", said Prof. Marcel Worring, Director of the Informatics Institute at the University of Amsterdam. "The most-heard questions across sectors are how to find and use that data to gain new insights and make informed decisions, but also how to enable reproducibility of the data, deploy semantic technologies and create a safe data sharing environment. Answering these questions requires a multi-stakeholder approach involving partners from academics, business and society. ADS bundles these forces. In Elsevier we've found a partner that has a proven track record in deploying technology to analyze data, enable data sharing and reuse and facilitate collaboration among researchers." "As a global technology company, we're engaging in data science and big data collaborations around the world", said Michiel Kolman, Senior Vice President Global Academic Relations at Elsevier. "But our company has its roots and its head office in the Netherlands so it's exciting to collaborate with ADS and local institutions to help develop our home city as a national and international data science hub, making it an even more attractive place for data science researchers. In addition to contributing to ADS' goals ourselves, we're looking forward to learn a lot from the companies and knowledge institutes that are part of the ADS network. Advancing data science is a multi-stakeholder endeavor." A number of projects have already started. These are focused on improving data search and reproducibility of research that will ultimately result in higher quality research outcomes. These projects entail: Both parties have committed to developing new projects together in the years to come, among other things providing corporate work experience programs for grad students and post-docs at Elsevier, and specialized Elsevier staff engaging in teaching the next generation data scientists. ADS is a platform and network organisation initiated by four Amsterdam-based knowledge institutes: University of Amsterdam (UvA), VU University, Amsterdam University of Applied Sciences (AUAS) and Centrum Wiskunde & Informatica (CWI). The institutions are well-known for their world-class research and education on data science.  ADS accelerates data science research by connecting, sharing and showcasing world-class technology, expertise and talent from Amsterdam on a regional, national and international level. Our research enables business and society to better gather, store, analyse and present data in order to gain valuable insights and make informed decisions. Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey - and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. http://www.elsevier.com


News Article | November 8, 2016
Site: www.prweb.com

WHAT:  The 2016 OPEN MINDS Technology & Informatics Institute brings together more than 500 executives and 30 innovative technology organizations to discuss the emerging technology tools executives need to improve outcomes, streamline decision-making and add value to the management and delivery of care for consumers with complex needs. The two-day event will reveal how organizations can better leverage the power of data analytics and technology innovations in order to gain a competitive advantage in a value-based market. Candace Saldarini, M.D., Director of Medical Strategy for ODH, Inc., a leading provider of behavioral health technology solutions and services, will present with IBM Watson Health on the importance of population health management and ways cognitive computing is now being used in healthcare including behavioral health and the health and human services marketplaces. Dr. Saldarini will also discuss how ODH’s flagship product, Mentrics, is transforming the management and economics of behavioral healthcare by delivering comprehensive and predictive insights, enabling a collaborative approach among key stakeholders. WHEN & WHERE: OPEN MINDS Technology & Informatics Institute Breakout Session: Population Health Management & Cognitive Computing Thursday, November 10, 2016, 11:30 a.m. – 12:45 p.m. EDT Marriott Wardman Park, 2660 Woodley Rd. NW, Washington, D.C. 20008 More information: https://technology.openminds.com/overview/ WHO:  Candace T. Saldarini, M.D., is the Director for Medical Strategy for ODH, Inc., a provider of data analytics solutions for the behavioral health field. In this role, she provides content expertise for its flagship product Mentrics, the leading edge comprehensive population health management platform designed to transform the management of behavioral healthcare systems. With more than 15 years of experience in clinical and managed behavioral healthcare, Dr. Saldarini has a proven track record as a direct care provider and as a system manager responsible for clinical and quality management. About ODH, Inc. ODH, Inc. is an innovative behavioral health technology and services solution company that leverages technology and clinical expertise to transform the delivery and economics of behavioral healthcare. ODH’s team of experts have decades of experience in the behavioral health, medical, clinical, pharmacy, business and data analytics and information technology fields, and is uniquely qualified to support the transformation of the management of behavioral healthcare. ODH is a subsidiary of Otsuka America, Inc. and part of the Otsuka Group of companies, an $11.9 billion global organization. Otsuka aspires to create new products for better health worldwide. ODH is a proud member of The White House’s Data-Driven Justice Initiative. For additional information on ODH, Inc., visit http://www.ODHSolutions.com and follow on Twitter @ODHInc.

Loading Informatics Institute collaborators
Loading Informatics Institute collaborators